Background
Autologous neutralizing antibodies (aNAbs) block outgrowth of substantial but variable fraction of reservoir viruses in people with HIV (PWH), and in rare early treated PWH, aNAbs can prevent viral rebound following treatment interruption. Here we characterized the aNAb response at the clonal level in a representative PWH who started treatment during chronic infection.
Methods
Participant-derived Env ectodomains were purified for isolates that were resistant or sensitive to polyclonal autologous contemporaneous IgGs. Purified Envs were analyzed by cryoEM, 3D variability analysis and used to sort individual autologous Env-specific IgG+ B cells. VDJ regions of antigen-specific B cells were sequenced to generate monoclonal aNAbs (mAbs), which were tested in TZM-bl neutralization assays against 8 pseudoviruses expressing distinct autologous inducible, replication-competent viral Envs. Instantaneous inhibitory potential (IIP), a parameter quantifying how many logs of single-round infection are blocked at a given dose, was calculated for each mAb.
Results
Cryo-EM structures showed higher conformational rigidity in the aNAb-sensitive Env compared to the aNAb-resistant Env. Clonal analysis revealed an oligoclonal B cell response against the resistant Env and a more diverse polyclonal B cell response against the aNAb-sensitive Env. 2 mAbs pulled out with resistant Env and 18 mAbs pulled out with sensitive Env were tested in pseudovirus neutralization assays. Surprisingly, the aNAb-resistant isolate was neutralized by 10 out of 20 mAbs (IC50 0.57-91.8 µg/mL, IIP50µg/mL 0.2-2.4). Moreover, 15 mAbs show high potency in neutralizing the sensitive isolate (IC50 0.01 – 1.77 µg/mL, IIP50µg/mL 0.9-6.7). 2 mAbs neutralized all 8 pseudoviruses and 7 mAbs exhibited partial cross-reactivity, neutralizing at least 3 of 8 pseudoviruses. Future experiments include testing the ability of the cross-reactive autologous mAbs to prevent viral outgrowth in QVOA.
Conclusions
We present compelling evidence that the IgG+ memory B cell pool in PWH contains Env-specific B cells with the potential to produce mAbs that neutralize the Env resistant to contemporaneous polyclonal IgGs (IC50 > 100 µg/mL) and even exhibit high cross-reactivity. In vivo, these mAbs might present at too low a concentration to effectively block viral replication. We demonstrate that autologous mAbs show potent and broad neutralization of autologous viruses with direct clinical relevance and key implications for a personalized functional cure.